EP2114373A1 - Dermatologische emulsion und verfahren zu ihrer herstellung - Google Patents

Dermatologische emulsion und verfahren zu ihrer herstellung

Info

Publication number
EP2114373A1
EP2114373A1 EP08701673A EP08701673A EP2114373A1 EP 2114373 A1 EP2114373 A1 EP 2114373A1 EP 08701673 A EP08701673 A EP 08701673A EP 08701673 A EP08701673 A EP 08701673A EP 2114373 A1 EP2114373 A1 EP 2114373A1
Authority
EP
European Patent Office
Prior art keywords
composition according
chosen
ethoxylated
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08701673A
Other languages
English (en)
French (fr)
Inventor
Françoise NIELLOUD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Priority to EP12170593A priority Critical patent/EP2564831A1/de
Publication of EP2114373A1 publication Critical patent/EP2114373A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/596—Mixtures of surface active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the present invention relates to the field of washing foaming liquid forms for the treatment of dermatological disorders, in particular scalp disorders such as seborrheic dermatitis.
  • Seborrheic dermatitis is a chronic inflammatory dermatological condition that mainly affects the head and face of the sebaceous glands. Seborrheic dermatitis is characterized by marked desquamation of the scalp and its margin, eyebrows and the nasolabial fold.
  • Seborrheic dermatitis treatments include the use of antifungal compounds such as azoles, tars, sulfites or zinc pyrithione, for example, to control the invasion of Pityrosporum and / or the use of anti-inflammatories.
  • antifungal compounds such as azoles, tars, sulfites or zinc pyrithione, for example, to control the invasion of Pityrosporum and / or the use of anti-inflammatories.
  • adequate treatments consist of daily treatment with an anti-dandruff shampoo containing selenium sulfite and / or zinc pyrithione.
  • Tar-based shampoo or containing ketoconazole may also be used.
  • Such shampoos should be applied to the scalp and left in place for about 10 minutes before rinsing.
  • the use of a moisturizing or emollient shampoo is recommended to limit drying of the scalp.
  • corticosteroids can be used locally.
  • BE 84515 discloses a composition containing hydrocortisone in a solvent mixture consisting of 15 to 60% aliphatic alcohol, 15 to 60% propylene glycol and 5 to 60% additional solubilizing agent.
  • EP 325 949 discloses a composition comprising at least 2.5% of corticosteroids, 25 to 80% of a nonionic surfactant, 0 to 70% of ethanol and 0 to 70% of propylene glycol in combination with an antimicrobial agent.
  • the patent application WO 96/27376 proposes a foam containing a corticoid, a foam-breaking agent, a propellant and a buffer.
  • this type of foam does not easily reach the scalp.
  • No. 6,607,733 discloses dermatological compositions in the form of O / W microemulsions containing an aqueous phase, a discontinuous fatty phase, a stabilizing system combining polyethoxylated and polypropoxylated emulsifiers with bridging substances making a bond between the microdroplets of the fatty phase.
  • a stabilizing system combining polyethoxylated and polypropoxylated emulsifiers with bridging substances making a bond between the microdroplets of the fatty phase.
  • the presence of these bridging agents is necessary to ensure the stability of these emulsions over time.
  • Such a solution is interesting but expensive and technically difficult to implement.
  • compositions that do not have the aforementioned drawbacks, that is to say a composition having good cosmetic properties and allowing easy application and good penetration of the active ingredient.
  • the applicant has thus developed a foaming composition in the form of an oil-in-water microemulsion type gel.
  • compositions according to the present invention allow the administration of the active ingredient in the area to be treated, ensure its good penetration into the dermis and also have dermatological and cosmetic performance quite interesting.
  • the compositions according to the present invention allow the treatment of skin conditions such as seborrheic dermatitis.
  • the rheological properties of the compositions according to the present invention allow an easy use in any point comparable to a shampoo.
  • the presentation in the form of shampoo with washing and foaming power allows cleaning of scalp present in the scalp and hair.
  • the compositions according to the present invention leave the hair soft and supple and are not irritating to the scalp.
  • compositions according to the present invention are stable over time and make it possible to avoid the precipitation of the active principle or a separation of the phases of the emulsion.
  • One of the objects of the present invention is therefore an oil-in-water microemulsion foaming gelled composition for washing and treating the scalp and the hair.
  • compositions according to the invention are also the use of the compositions according to the invention as a medicament and for the manufacture of a medicament for treating dermatological conditions of the skin and scalp.
  • the invention therefore relates more precisely to a gelled foaming composition in the form of a stable oil-in-water microemulsion, comprising a fatty phase of microdroplets dispersed in an aqueous phase and a dermatological active ingredient, characterized in that it comprises a surfactant system consisting of at least one ethoxylated nonionic surfactant; at least one cosurfactant stabilizing the ethoxylated nonionic surfactant; at least one non-ethoxylated hydrophilic nonionic surfactant; at least one foaming agent selected from the group of anionic surfactants.
  • a surfactant system consisting of at least one ethoxylated nonionic surfactant; at least one cosurfactant stabilizing the ethoxylated nonionic surfactant; at least one non-ethoxylated hydrophilic nonionic surfactant; at least one foaming agent selected from the group of anionic surfactants.
  • stabilizing cosurfactant the ethoxylated nonionic surfactant a surfactant being placed between the other surfactant molecules and providing flexibility and fluidity to interfacial films, thereby stabilizing the interfacial films between oil and water.
  • the term "foaming agent” a surfactant that can be placed at the water-air interface, this having the effect of stabilizing the formed foam.
  • the composition according to the invention does not contain a bridging agent.
  • bridging agent is understood to mean a molecule comprising at least two regions capable of interacting with the oil droplets by a hydrophobic interaction, thereby forming a bridge between two or more oil droplets, and a region interacting with the aqueous phase. by a hydrophilic interaction.
  • the active ingredient contained in the composition according to the present invention is a dermatological active ingredient, with therapeutic virtues vis-a-vis cutaneous affections of the skin and / or the scalp.
  • the dermatological active ingredient is, for example, a non-hydrous active ingredient that is preferably solubilized in the fatty phase of the microemulsion.
  • Corticosteroids are particularly well suited as dermatological active ingredient according to the present invention.
  • Corticosteroids of the present invention may be chosen from the group comprising alclometasone dipropionate, amcinonide, beclomethasone dipropionate, bethamethasone benzoate, betamethasone valerate, bethamethasone dipropionate, bethamethasone valerate, budesonide, clobetasol propionate, preferably clobetasol propionate, clobetasol butyrate, desonide, deoximetasone, dexamethasone, diflucortolone diacetate, diflucortolone valerate, flurandrenolone, fluprednidene acetate, fluocortolone, fluocortin butyl, fluocinonide, fluocinolone acetonide, fluclorolone acetonide, flumetasone pyvalate, fusediline hydrochloride, flumetholone, halcinonide, hydrocort
  • the active ingredient is advantageously betamethasone valerate.
  • the antifungal active principles are of interest in the context of the present invention.
  • the antifungals are chosen from the group comprising imidazoles, non-imidazole pyridones, morpholines and allylamines.
  • the imidazole may advantageously be chosen from the group comprising ketoconazole, bifonazole, clotrimazole, econazole, fenticonazole, isoconazole, miconazole, omoconazole, oxyconazole, sulconazole and tioconazole.
  • the non-imidazole pyridone is advantageously cyclopiroxamine.
  • morpholine is amorolfine.
  • Allylamine may be selected from the group consisting of terbinafme and tolnaftate.
  • the anti-seborrhoeic active ingredients such as, for example, selenium sulphide and benzoyl peroxide, may be used according to the present invention.
  • the amount of dermatological active ingredient is included in weight between
  • 0.001% and 5% advantageously between 0.01% and 1%, more advantageously still between 0.05% and 1%, more preferably still equal to 0.1% of the total weight of the composition.
  • the aqueous phase may contain, in addition to water, cosmetically acceptable solvents such as for example glycerol, propylene glycol, sorbitol, ethanol, polyethylene glycols, isopropanol, one or more water-soluble compounds such as acids or bases, dyes, moisturizing, soothing, healing, exfoliating, antioxidant or any other additive or adjuvant not detrimental to the stability of microemulsions.
  • cosmetically acceptable solvents such as for example glycerol, propylene glycol, sorbitol, ethanol, polyethylene glycols, isopropanol
  • water-soluble compounds such as acids or bases, dyes, moisturizing, soothing, healing, exfoliating, antioxidant or any other additive or adjuvant not detrimental to the stability of microemulsions.
  • the aqueous phase may also contain one or more water-soluble compounds such as acids or bases, dyes, moisturizing, soothing, healing, exfoliating, antioxidant or any other additive or adjuvant not detrimental to the stability of microemulsions.
  • water-soluble compounds such as acids or bases, dyes, moisturizing, soothing, healing, exfoliating, antioxidant or any other additive or adjuvant not detrimental to the stability of microemulsions.
  • the amount of aqueous phase of the composition according to the present invention is advantageously comprised by weight between 30% and 60%, more preferably between 35% and 55% of the total weight.
  • the fatty phase of the composition is of great importance in the context of the present invention. Indeed, the microdroplets of this fatty phase (discontinuous phase of the microemulsion) serve to solubilize the non-water-soluble active principle and to convey the latter at the level of the scalp, thus ensuring its vectorization in the dermis.
  • the bioavailability of the composition according to the present invention is greatly improved compared to a composition whose active ingredient would be in the form of dispersed particles with a very limited transcutaneous passage.
  • the fatty phase of the composition according to the invention has the emollient properties to preserve the skin and scalp.
  • the amount of fatty phase in the composition according to the present invention is advantageously between 0.5% and 20% by weight, more advantageously between 2% and 18%, more preferably between 2.5% and 15%, and still more preferably between 5% and 10% of the total weight of the composition.
  • the components of the fatty phase may be chosen from the group comprising vegetable or mineral oils, triglycerides, monoglycerides, diglycerides, fatty acid derivatives, fatty acid esters, natural oils, hydrogenated or not, synthetic or not, hydrocarbons, cyclic or aliphatic, linear or branched (saturated or not), volatile or nonvolatile silicones, organomodified or not, soluble or not, perfluorinated or fluorinated oils, polybutenes and polyisobutenes, fatty esters in the form of liquid, used alone or as a mixture.
  • it may be a paraffin oil, octododecyl myristate, isopropyl myristate, tricaprilic glycerol, capric-caprylic glyceride, used alone or in admixture.
  • organomodified silicone is meant a silicone comprising one or more functional groups attached to the siloxane chain, optionally via a hydrocarbon radical.
  • groups include polyethyleneoxy, polypropylenoxy optionally containing alkyl groups such as alkyl methicone copolyol sold by Dow Corning under the name Q2 5200.
  • the ethoxylated nonionic surfactant may be selected from the group consisting of ethoxylated fatty alcohols, ethoxylated fatty acids, ethoxylated fatty acids etherified with alkyl or alkenyl groups, ethoxylated fatty acids esterified with alkyl or alkenyl groups, ethoxylated esters of ethoxylated fatty acids. saturated or unsaturated fatty acids, glycerol, propylene glycol, glycol, polyethylene glycol, sorbitan, mixtures of glycerides and caprylic esters of polyethylene glycol, copolymers of ethylene oxide and propylene (type
  • the amount of ethoxylated nonionic surfactant present in the composition according to the present invention is advantageously less than 20% by weight of the total weight of the composition, more preferably between 10% and 20% of the total weight.
  • the present composition comprises at least one cosurfactant stabilizing the ethoxylated nonionic surfactant.
  • the amount of stabilizer will be defined relative to the ethoxylated nonionic surfactant.
  • the cosurfactant: ethoxylated nonionic surfactant ratio may advantageously be between 1: 2 and 1: 6, more advantageously between 1: 2 and 1: 4, depending on the nature of both the cotensioactive and the ethoxylated nonionic surfactant.
  • the total amount of ethoxylated nonionic surfactant and stabilizing cosurfactant is advantageously comprised by weight of between 15% and 40%, more preferably between 20% and 35% of the total weight of the composition.
  • the co-surfactant stabilizing the ethoxylated nonionic surfactant in a composition according to the present invention may be chosen from the group comprising non-ethoxylated esters of saturated or unsaturated fatty acids and glycerol, polyglycerol, propylene glycol, glycol, polyethylene glycol or sorbitan, such as triglycerol diisostearate, triglycerol oleate, propylene glycol monolaurate, propylene glycol monocaprylate, sorbitan monostearate.
  • the amount by weight of non-ethoxylated hydrophilic nonionic surfactant is preferably from 1 to 30% by weight, more preferably from 10 to 30%, more preferably from 13 to 25% by weight.
  • the non-ethoxylated hydrophilic nonionic surfactants suitable for the implementation of the present composition may be chosen from surfactants derived from sugars, esters of fatty acids and sucrose, sucrose or glucose.
  • the non-ethoxylated hydrophilic nonionic surfactants may be chosen from the group comprising glucoside derivatives such as alkylglucosides and alkylpolyglucosides, having carbon chains from Cs to C22 with a number of glucose units of 1 to 7, for example octylglucoside.
  • the pH of the compositions according to the present invention is advantageously between 3 and 8, more advantageously between 4 and 6. The choice of pH will depend on the active ingredient retained and its chemical structure.
  • the pH is advantageously adjusted by the addition of lactic acid.
  • the composition of the present invention also includes an anionic foaming agent to enhance foaming and cleaning functionality useful for the desired applications of the present invention.
  • the foaming agent according to the present invention may be chosen from the group of anionic surfactants comprising the sodium, ammonium, amine, aminoalcohol or magnesium salts of the following compounds: alkyl sulphates, alkyl ether sulphates, alkylamido ether sulphates, alkylarylpolyethersulfates, alkyl monoglyceride sulphates, alkyl monoglycerides ether sulphates, alkyl monoglyceride sulphonates, alkylsulphonates, alkylphosphates, alkyl isethionates, alkylcarboxylates, alkyl ether carboxylates, alkyl ether amidocarboxylates, alkylamidesulphonates, alkylarylsulphonates,
  • composition according to the present invention may further comprise adjuvants conventionally used in dermatological or cosmetic compositions such as shampoos.
  • the present composition may thus comprise stabilizing agents or foam reinforcers such as fatty acid amides, alkylamides, mono- and diethanolamides, isopropanolamides of fatty acids.
  • the stabilizing agent or foam booster will be coconut fatty acid diethanolamide, for example Comperlan KD (Cognis).
  • the amount of stabilizing agent or foam booster in the present composition may advantageously be between 0% and 10% by weight, advantageously between 2% and 8%, for example 6% by weight relative to the total weight of the composition.
  • composition according to the present invention is thus in the form of an oil-in-water microemulsion, in which the non-water-soluble dermatological active ingredient is found in the fatty phase.
  • This fatty phase is stabilized thanks to the system of surfactants and cosurfactant used in the present composition.
  • this composition may contain thickeners chosen in particular from non-bridging agents such as electrolytes (preferably sodium chloride or sodium citrate), carbomers or xanthan gums.
  • non-bridging agents such as electrolytes (preferably sodium chloride or sodium citrate), carbomers or xanthan gums.
  • the amount of thickening agent in the present invention may be between 0 and 4% by weight, advantageously between 1% and 3% of the total weight of the composition.
  • the addition of NaCl to the present composition makes it possible to advantageously increase the viscosity of said composition.
  • the present composition may thus comprise up to 2%, advantageously 1% NaCl, by weight relative to the total weight of the composition.
  • the compositions are in the form of liquids, particularly in the form of viscous liquids.
  • preservatives may be added.
  • the preservatives suitable for the implementation of the present composition may be chosen from conventional preservatives of topical medicaments such as acids and their salts (boric acid, benzoic acid, lactic acid, sorbic acid), alcohols (benzyl alcohol). phenoxyethanol, chlorocresol), parahydroxybenzoic acid esters (methyl, ethyl, propyl, butyl, parabens), and imidazolidinurea derivatives.
  • preservatives will be selected from the group comprising sorbic acid and its salts, in particular potassium sorbate used at a concentration of 0.01 to 0.2% by weight.
  • compositions according to the invention are more particularly used as shampoo for the treatment of the scalp.
  • the active ingredient chosen is betamethasone valerate
  • the composition according to the invention is more particularly intended for the treatment of seborrheic dermatitis of the skin in general, and of the scalp in particular.
  • the composition is applied to wet hair.
  • a light massage is performed during which a foam is formed, followed by a thorough rinsing after having respected a time of installation.
  • a second application can be made followed by a thorough rinsing with water.
  • the emollient effect of the composition according to the present invention makes its use particularly suitable for the treatment of dermatological disorders such as seborrheic dermatitis. Indeed, this condition being characterized by redness and irritation, the use of the composition according to the present invention can limit the skin dryness phenomena traditionally observed.
  • the compositions according to the present invention can be manufactured according to conventional techniques of the pharmaceutical and cosmetic industry.
  • the fat phase will be intimately mixed with the various surfactants and the active calcium. Said mixture may be subjected to homogenization by mechanical stirring before emulsification.
  • the aqueous phase containing any water-soluble adjuvants such as for example NaCl will be prepared separately, and subsequently incorporated into the fatty phase.
  • the step of incorporating the aqueous phase into the fatty phase is carried out with stirring, at a speed and for a time sufficient to achieve the transparency of the composition.
  • the pH of the microemulsion thus obtained can be adjusted by adding an acidic or basic solution.
  • the incorporation of the active ingredient can be carried out by stirring until complete dissolution at room temperature.
  • the use of lactic acid to adjust the pH will be preferred.
  • the invention therefore also relates to a process for preparing a composition according to the invention, comprising the following successive steps: mixing the fatty phase with the surfactant system and homogenizing the mixture by mechanical stirring; - Mixing the various adjuvants in the aqueous phase, such as the thickening agent; incorporating the aqueous phase in the fatty phase with stirring, at a speed and for a time sufficient to achieve the transparency of the composition; optionally adjust the pH of the emulsion by adding an acidic or basic solution; incorporate the active ingredient by stirring until complete dissolution thereof at room temperature.
  • the invention also relates to a composition as previously described as a medicament.
  • the invention also relates to the use of a composition as described above for the manufacture of a medicament for treating dermatological disorders, the scalp and seborrheic dermatitis.
  • the invention also relates to the use of a composition as previously described as a cosmetic.
  • Texapon N 70® sodium laureth sulfate and Texapon NSO® were obtained from Cognis.
  • Ondina 68® and Primol 352® mineral oil were obtained respectively from Schell and Exxon Mobil.
  • PEG-40 Labrasol hydrogenated castor oil was obtained from Gattefosse.
  • - Comperlan KD® MEA cocamide was obtained from Cognis.
  • Decylglucoside Oramix NS 10® was obtained from Seppic.
  • Pluric oleic and plurol diisostearic were obtained from Gattefosse.
  • Example 1 Two microemulsions lacking active principle (bases) were prepared and analyzed. Their composition is shown in Table 1 and their analyzes are collated in Table 2. The percentages indicate a concentration by weight of the corresponding product in solution in water.
  • Both emulsions are stable, transparent and have good sensory analysis and correct viscosity.
  • Table 1 Formulation of microemulsions lacking active principle.
  • the foaming power is obtained by measuring the foam height after a churn of 90 seconds.
  • Soil resistance is a measure of the foam height after a 90 second churn and incorporation of one or more ml of artificial soil.
  • the emulsion to be analyzed (40 ml) was placed in a standard test tube.
  • the soil consists of lanolin 5%, paraffin oil 5% and dioxane qs 100%. 1 ml of soil was added to the emulsion. The solution was agitated for 90 seconds then the height of foam H1 was measured. After 20 seconds rest, 1 ml of soil was again added, the solution was stirred for 30 seconds and the height of H2 foam was measured.
  • the wetting power is measured according to a method adapted from AFNOR NF 73-406 and NF-73-420, consisting of measuring the time required for the emulsion to completely wet a standard cotton disc of 3 cm in diameter. The measurements were taken for different concentrations of surfactant and the wetting power corresponds to the concentration of surfactant for which the wetting time is 100 seconds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP08701673A 2007-01-26 2008-01-25 Dermatologische emulsion und verfahren zu ihrer herstellung Withdrawn EP2114373A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12170593A EP2564831A1 (de) 2007-01-26 2008-01-25 Hautemulsion und ihr Herstellungsverfahren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0752901A FR2911781B1 (fr) 2007-01-26 2007-01-26 Emulsion dermatologique et procede de preparation
PCT/EP2008/050879 WO2008095796A1 (fr) 2007-01-26 2008-01-25 Emulsion dermatologique et procede de preparation

Publications (1)

Publication Number Publication Date
EP2114373A1 true EP2114373A1 (de) 2009-11-11

Family

ID=38655394

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08701673A Withdrawn EP2114373A1 (de) 2007-01-26 2008-01-25 Dermatologische emulsion und verfahren zu ihrer herstellung
EP12170593A Withdrawn EP2564831A1 (de) 2007-01-26 2008-01-25 Hautemulsion und ihr Herstellungsverfahren

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP12170593A Withdrawn EP2564831A1 (de) 2007-01-26 2008-01-25 Hautemulsion und ihr Herstellungsverfahren

Country Status (7)

Country Link
US (1) US20100068307A1 (de)
EP (2) EP2114373A1 (de)
JP (1) JP5313926B2 (de)
AR (1) AR065032A1 (de)
CA (1) CA2676232A1 (de)
FR (1) FR2911781B1 (de)
WO (1) WO2008095796A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20091075A1 (it) * 2009-06-17 2010-12-17 Valetudo Srl Composizioni farmaceutiche e cosmetiche comprendenti lactoferrina ciclopirox acido etidronico
US9254296B2 (en) 2009-12-22 2016-02-09 Leo Pharma A/S Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture
WO2011076206A1 (en) * 2009-12-22 2011-06-30 Leo Pharma A/S Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
US8933134B2 (en) 2010-06-09 2015-01-13 L'oreal Compositions containing agar and a softening agent
JP6356382B2 (ja) * 2012-12-21 2018-07-11 ロレアル 化粧品組成物
WO2014134427A1 (en) * 2013-02-28 2014-09-04 Precision Dermatology, Inc. Controlling the bioavailability of active ingredients in topical formulations
US10111956B2 (en) * 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
CN104523592B (zh) * 2015-01-26 2017-03-15 湖北工业大学 甲泼尼龙醋酸酯注射用自微乳制剂及其制备方法
KR102607078B1 (ko) * 2016-08-10 2023-11-28 주식회사 엘지생활건강 오일을 고함유하는 세정제 조성물
DE102016225873A1 (de) * 2016-12-21 2018-06-21 Henkel Ag & Co. Kgaa Mittel und Verfahren zur temporären Verformung keratinhaltiger Fasern
JP2019014679A (ja) * 2017-07-07 2019-01-31 ロレアル 超微細ｏ／ｗエマルションの形態のケラチン繊維のためのシリコーン非含有組成物
US11504327B1 (en) * 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion
CN111249221A (zh) * 2020-02-28 2020-06-09 天津金耀药业有限公司 一种二氟可龙乳膏酯及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1180974A (en) * 1982-04-26 1985-01-15 Thomas E. Cook Foaming surfactant compositions
US4536318A (en) * 1982-04-26 1985-08-20 The Procter & Gamble Company Foaming surfactant compositions
LU84515A1 (fr) 1982-12-09 1984-10-22 Oreal Composition stable pour corticotherapie locale a forte concentration hydrocortisone solubilisee
DE68900548D1 (de) 1988-01-13 1992-01-30 Sanol Arznei Schwarz Gmbh Konzentrierte corticosteroide enthaltende loesungen und verfahren zu deren herstellung.
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
DE19509079A1 (de) * 1995-03-15 1996-09-19 Beiersdorf Ag Kosmetische oder dermatologische Mikroemulsionen
DE19641672A1 (de) * 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US6075056A (en) * 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
FR2820038B1 (fr) * 2001-01-29 2004-07-02 Dermaconcept Jmc Composition dermatologique a usage veterinaire comprenant une base sphingoide
DE10149373A1 (de) * 2001-10-06 2003-04-30 Beiersdorf Ag Antitranspirantprodukt auf Basis von Mikroemulsionsgelen
FR2850278B1 (fr) * 2003-01-24 2005-02-25 Gattefosse Ets Sa Utilisation du 2-hydroxymethyltetrahydropyranne comme excipient dans une composition cosmetique ou pharmaceutique
BRPI0412975A (pt) * 2003-08-25 2006-10-03 Foamix Ltd espuma penetrante para uso farmacêutico
FR2883475A1 (fr) * 2005-03-25 2006-09-29 Oreal Emulsion h/e moussante et son utilisation dans le domaine cosmetique
US20060217283A1 (en) * 2005-03-25 2006-09-28 L'oreal Foaming O/W emulsion and use thereof in cosmetics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008095796A1 *

Also Published As

Publication number Publication date
JP5313926B2 (ja) 2013-10-09
US20100068307A1 (en) 2010-03-18
AR065032A1 (es) 2009-05-13
EP2564831A1 (de) 2013-03-06
FR2911781A1 (fr) 2008-08-01
FR2911781B1 (fr) 2009-03-20
WO2008095796A1 (fr) 2008-08-14
JP2010516743A (ja) 2010-05-20
CA2676232A1 (fr) 2008-08-14

Similar Documents

Publication Publication Date Title
WO2008095796A1 (fr) Emulsion dermatologique et procede de preparation
EP1353629B1 (de) Durchscheinende nanoemulsion, verfahren zur deren herstellung, und deren verwendungen in kosmetika, dermatologie und/oder ophthalmologie
EP0815846B1 (de) Ultrafeine Öl-in-Wasser Emulsion, die eine vernetzte, zu mindestens 90% neutralisierte Poly(-2-Acrylamide-2-Methylpropane Sulfonsäure) enthält und Verfahren zur Herstellung
EP0974341B2 (de) Schäumende und konditionierende Reinigungs-Zusammensetzung
FR2794125A1 (fr) Composition sous forme d'emulsion huile-dans-eau et ses utilisations notamment cosmetiques
EP0987014A1 (de) Verdickungsmittel und verdickendes Copolymer enthaltende hydrophile Emulsion, diese enthaltende Zusammensetzungen und ihre Verwendung
EP2097077A1 (de) Benzoyl-peroxid mit zusammensetzungen, mindestens einem naphthoesäurederivat und mindestens einer polyurethanpolymerartigen verbindung oder derivaten davon und verwendung
EP1136058A1 (de) Zusammensetzung vom Typ-Wasser-in-Öl Emulsion und ihre Verwendung in der Kosmetik
KR101145060B1 (ko) 제형 안정성을 개선시킨 ｏ／ｗ 형 화장료 조성물
EP0692241B1 (de) Gelartige kosmetische und/oder dermatologische Zusammensetzung enthaltend hohle Teilchen und eine grosse Menge an Lösungsmittel
EP0987015A1 (de) Verdickungsmittel und Alkylether eines Polysaccharides enthaltende hydrophile Emulsion, diese enthaltende Zusammensetzungen und ihre Verwendung
EP1616554B1 (de) Feine Ö/W-Emulsion und ihre Verwendung im Kosmetikbereich
EP1704852A1 (de) Schäumende O/W-Emulsion und ihre Verwendung in der Kosmetik
EP1093801B1 (de) W/O-Emulsion und ihre Verwendung insbesondere in der Kosmetik
EP1618864B1 (de) Öl-in-Wasser-Emulsionen mit hohem Ölgehalt und deren Verwendung in der Kosmetik
FR2802096A1 (fr) Composition, notamment cosmetique, comprenant un acide triterpene pentacyclique
EP2116220A1 (de) Kosmetische Zusammensetzung, die eine durch PIT-Verfahren hergestellte Emulsion umfasst
EP1027884A1 (de) Diolacetylen enthaltende Zusammensetzung und deren topische Anwendung
FR2777182A1 (fr) Compositions cosmetiques ou dermotalogiques pour application topique sous forme d'emulsions de type huile-dans-eau renfermant des esters liquides d'acide gras et d'alcool gras et des phospholipides et leur procede de preparation
EP3302421B1 (de) Zusammensetzungen mit mindestens einem dispergierten wirkstoff und lipid-mikrokapseln
FR2777194A1 (fr) Compositions cosmetiques ou dermatologiques sous forme d'emulsions de type eau-dans-huile renfermant des hydrocarbures ramifies liquides et des phospholipides et leur procede de preparation
FR2777180A1 (fr) Compositions cosmetiques ou dermatologiques sous forme d'emulsions de type eau-dans-huile renfermant des hydrocarbures legers et des phospholipides et leur procede de preparation
FR2777181A1 (fr) Compositions cosmetiques ou dermatologiques sous forme d'emulsions de type eau-dans-huile renfermant des cyclomethicones et des phospholipides et leur procede de preparation
FR2777195A1 (fr) Compositions cosmetiques ou dermatologiques sous forme d'emulsions de type eau-dans-huile renfermant des hydrocarbures ramifies liquides et des phospholipides et leur procede de preparation
FR2755850A1 (fr) Compositions cosmetiques detergentes et utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090728

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100602

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150801